<DOC>
	<DOCNO>NCT02715089</DOCNO>
	<brief_summary>The purpose study explore precise treatment hepatobiliary cancer patient evaluate drug safety , progression free overall survival . This trial study base genetic test , therapeutic target drug administer accord genetic test report . Patients genetic abnormality ( mutation , amplification , translocation ) may benefit precise treatment target particular genetic abnormality . The identification genetic abnormality may help treat hepatobiliary cancer patient well .</brief_summary>
	<brief_title>Precise Treatment Hepatobiliary Cancers ( PTHBC )</brief_title>
	<detailed_description>The genetic test perform eligible subject study , therapeutic target drug administer accord genetic test report . While precise treatment , follow-up conduct evaluate efficacy safety target drug subject , overall survival . Study Type : Non-Interventional . Masking : Open Label .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<criteria>Age 18 65 , male female . Radiologically pathologically confirm hepatobiliary cancer stage IV . Palliative care prefer . The result nextgeneration sequencing ( NGS ) test show patient gene mutation also treat right commercial product approve China Food Drug Administration ( CFDA ) Food Drug Administration ( FDA ) . ECOG performance status 02 . Life expectancy ≥3 month . Voluntarily participate study agree sign inform consent form . Hepatobiliary cancer patient stageIIII , follow item eligible screening.Such , suitable treatment radical resection , radical resection evaluation unmeasurable . The result NGS test show patient gene mutation , gene mutation medicine . ECOG performance status ≥ 3 . Female patient pregnant use contraceptive method birth control . History presence serious cardiovascular cerebrovascular abnormality . Abnormalities hepatic renal function , jaundice , ascites , bilirubin ≥ 1.5×ULN , alkaline phosphatase ≥ 3×ULN , persistent protein urine≥ grade 3 ( accord National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] v4.0 ) , creatinine ratio &gt; 3.5g/24 hour , renal failure . Persistent infection &gt; grade 2 ( accord National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] v4.0 ) . Patient underwent major operation 4 week prior screen yet recover operation . Patient epilepsy , know untreated brain metastasis . The presence wound , ulcer fracture heal , past history transplantation . The presence bleed event ≥grade 3 ( accord National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] v4.0 ) , present evidence past history coagulation dysfunction disorder . Known human immunodeficiency virus ( HIV ) infection history . Patient drug abuse unstable compliance . The presence unresolved toxicity cause previous treatment/operation &gt; grade 1 ( accord National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] v4.0 ) , except alopecia , anemia hypothyroidism ) . Investigator consider patient enrol study careful assessment . The subject participate clinical trial meantime .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>NGS</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Biliary Tract Neoplasms</keyword>
	<keyword>Hepatobiliary Neoplasms</keyword>
</DOC>